DirectMeds owns two niches - flat $147 tirzepatide and needle-free drops. The reasons to look elsewhere:
- Semaglutide price - three rivals beat $147/month by a wide margin.
- Support - it's a lean, medication-first service with no coaching layer.
- Injectable-standard preference - if you want the trial-validated injectable route with richer clinical wrap-around, others compete hard.


